# GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer

> **NCT00358566** · PHASE3 · TERMINATED · sponsor: **Pharmexa A/S** · enrollment: 360 (actual)

## Conditions studied

- Advanced Unresectable Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** GV1001
- **DRUG:** Gemcitabine (Chemotherapy)

## Key facts

- **NCT ID:** NCT00358566
- **Lead sponsor:** Pharmexa A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-06
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 360 (ACTUAL)
- **Why stopped:** Preliminary data showed no survival benefit in the GV1001 group compared to the gemcitabine group.
- **Last updated:** 2008-05-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358566, "GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00358566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*